Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG-2 umbrella trial in younger adults with acute myeloid leukemia
2026-525759-96-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of quizartinib, midostaurin, venetoclax, cytarabine, daunorubicin and 2 more in acute myeloid leukemia (AML) (5 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: MRD-negative remission after first induction, MRD-negative remission after second chemotherapy cycle and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
quizartinibmidostaurinvenetoclaxcytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2026-525759-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525759-96-00.